HCV and diabetes: towards a ‘sustained’ glycaemic improvement after treatment with DAAs? C. Fabrizio, A. Procopio Clinical Microbiology and Infection Volume 23, Issue 5, Pages 342-343 (May 2017) DOI: 10.1016/j.cmi.2016.09.021 Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions
Fig. 1 Modification of fasting glucose (FG) levels during and after treatment. Dotted line shows trend of mean glycaemia levels. Bars represent percentage of patients with decrease of FG levels ≥20 mg/dL. Time points are expressed in weeks (w). Clinical Microbiology and Infection 2017 23, 342-343DOI: (10.1016/j.cmi.2016.09.021) Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions